MIME-Version: 1.0 Server: WebSTAR/2.1 ID/32304 Message-ID: Date: Sat, 13 Dec 1997 21:38:38 GMT Last-Modified: Tue, 01 Jul 1997 00:21:00 GMT Content-type: text/html Content-length: 3450 Technology R&D


HomeAbout EPIXMS-325Technology R&DNews
PublicationsEmployment OpportunitiesInvestor InfoRequest Information


Proprietary Technology

The products under development by EPIX are based upon its proprietary biophysics technology platform. The Company's product candidates are small molecule chelates (soluble metal-organic complexes) containing a magnetically active metal element which elicit a strong MRI signal and are designed to be safely excreted through the kidneys over time. EPIX has developed significant expertise in the design, synthesis and characterization of metal-containing complexes for in vivo use. Compared to non-targeted contrast agents used in MRI today, EPIX believes that its proprietary technology platform will enable it to design contrast agents capable of targeting specific tissues or organs by binding to particular proteins. The EPIX biophysics technology platform consists of two key elements: Receptor-Induced Magnetic Enhancement (RIME), and Enzyme Sensing Technology.

Chemical Structure of MS-325

MS-325 fitting into albumin binding site


FAQ's/Topics

What is Receptor-Induced Magnetic Enhancement?

What is Enzyme Sensing Technology?

MS-325 Development Program

EPIX R&D Programs


© 1997, EPIX Medical, Inc.

E-mail us at info@epixmed.com